Krishnan Nandabalan is Director & 10% Owner at BioXcel Therapeutics, Inc. (BTAI). They have made 4 open-market trades across 1 company since 2018, most recently 2023-04-06.
CIK 0001733387
1 open-market purchase totalling $5K since 2018, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BTAI | 60,000 | $4K |
Shares reported on the most recent Form 4, priced at the 2023-04-10 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BTAI | SELL · 10b5-1 | 2023-04-06 | 2023-04-10 | $17.32 | $1.0M | +22.2% | +65.1% | -41.4% |
| BTAI | SELL | 2023-01-04 | 2023-01-06 | $22.01 | $2.6M | +28.1% | +30.6% | -24.8% |
| BTAI | SELL | 2022-11-10 | 2022-11-14 | $15.00 | $900K | -3.6% | +17.9% | +101.4% |
| BTAI | SELL | 2021-06-25 | 2021-06-29 | $30.83 | $29.2M | -7.2% | -13.3% | +5.1% |
| BTAI | BUY | 2018-11-29 | 2018-11-30 | $4.92 | $5K | -16.1% | -22.5% | +70.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.